{
  "authors": [],
  "date_download": "2022-08-16 17:13:11",
  "date_modify": "2022-08-16 17:13:11",
  "date_publish": "2022-08-05 10:04:25",
  "description": "Press release content from Business Wire. The AP news staff was not involved in its creation.",
  "filename": "article_science-technology-health-clinical-trials-44615f8e61574513bfada1e4b8caac84_1660669991.html",
  "image_url": "https://apnews.com/images/PaidContent3.png",
  "language": "en",
  "localpath": "C:\\Users\\USUARIO/news-please-repo//data/2022/08/16/apnews.com/article_science-technology-health-clinical-trials-44615f8e61574513bfada1e4b8caac84_1660669991.html",
  "title": "Galactosemia Drug Pipeline Market Report 2022 Featuring Applied Therapeutics, Jaguar Gene Therapy, & BridgeBio Pharma",
  "title_page": "Galactosemia Drug Pipeline Market Report 2022 Featuring Applied Therapeutics, Jaguar Gene Therapy, & BridgeBio Pharma - ResearchAndMarkets.com",
  "title_rss": "NULL",
  "source_domain": "apnews.com",
  "maintext": "Press release content from Business Wire. The AP news staff was not involved in its creation.\nPress release content from Business Wire. The AP news staff was not involved in its creation.\nDUBLIN--(BUSINESS WIRE)--Aug 5, 2022--\nThe �Galactosemia- Pipeline Insight, 2022� clinical trials has been added to ResearchAndMarkets.com�s offering.\nThis Galactosemia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Galactosemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n�Galactosemia- Pipeline Insight, 2022� report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Galactosemia pipeline landscape is provided which includes the disease overview and Galactosemia treatment guidelines.\nThe assessment part of the report embraces, in depth Galactosemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Galactosemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.\nADVERTISEMENT\nReport Highlights\nThe companies and academics are working to assess challenges and seek opportunities that could influence Galactosemia R&D. The therapies under development are focused on novel approaches to treat/improve Galactosemia.\nGalactosemia Emerging Drugs Chapters\nThis segment of the Galactosemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.\nGalactosemia Emerging Drugs\nAT-007: Applied therapeutics\nAT-007 is an investigational, novel Aldose Reductase Inhibitor (ARI) being developed for the treatment of several rare diseases. AT-007 is a potent and selective compound, which crosses the blood brain barrier into the Central Nervous System (CNS penetrant). AT-007 has received both Orphan Drug and Pediatric Rare Disease designations from the FDA for the treatment of Galactosemia, a rare metabolic disease, and Phosphomannomutase 2 Deficiency - a Congenital Disorder of Glycosylation (PMM2-CDG). AT-007 is a once-daily oral compound that inhibits the enzyme Aldose Reductase. Aldose Reductase plays a crucial role in the pathogenesis of Galactosemia. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Galactosemia.\nJAG 101: Jaguar Gene Therapy\nJaguar is advancing JAG101, an investigational gene therapy currently in preclinical development that aims to deliver a gene replacement solution to address the root cause of Type 1 galactosemia by delivering the functional GALT gene via the AAV9 vector.\nADVERTISEMENT\nGalactosemia: Therapeutic Assessment\nThis segment of the report provides insights about the different Galactosemia drugs segregated based on following parameters that define the scope of the report, such as:\nMajor Players in Galactosemia\nThere are approx. 5+ key companies which are developing the therapies for Galactosemia. The companies which have their Galactosemia drug candidates in the most advanced stage, i.e. phase III include, Applied therapeutics.\nPhases\nThe report covers around 5+ products under different phases of clinical development like\nLate stage products (Phase III)\nMid-stage products (Phase II)\nEarly-stage product (Phase I) along with the details of\nPre-clinical and Discovery stage candidates\nDiscontinued & Inactive candidates\nRoute of Administration\nGalactosemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.\nProducts have been categorized under various ROAs such as\nIntra-articular\nIntraocular\nIntrathecal\nIntravenous\nOphthalmic\nOral\nParenteral\nSubcutaneous\nTopical\nTransdermal\nMolecule Type\nProducts have been categorized under various Molecule types such as\nOligonucleotide\nPeptide\nSmall molecule\nProduct Type\nDrugs have been categorized under various product types like Mono, Combination and Mono/Combination.\nADVERTISEMENT\nGalactosemia: Pipeline Development Activities\nThe report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Galactosemia therapeutic drugs key players involved in developing key drugs.\nPipeline Development Activities\nThe report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Galactosemia drugs.\nGalactosemia Report Insights\nGalactosemia Pipeline Analysis\nTherapeutic Assessment\nUnmet Needs\nImpact of Drugs\nGalactosemia Report Assessment\nPipeline Product Profiles\nTherapeutic Assessment\nPipeline Assessment\nInactive drugs assessment\nUnmet Needs\nKey Players\nApplied therapeutics\nJaguar Gene Therapy\nBridgeBio Pharma\nKey Products\nAT-007\nJAG 101\nBBP-818\nFor more information about this clinical trials report visit https://www.researchandmarkets.com/r/kwgwz9\nView source version on businesswire.com:https://www.businesswire.com/news/home/20220805005176/en/\nCONTACT: ResearchAndMarkets.com\nLaura Wood, Senior Press Manager\npress@researchandmarkets.com\nFor E.S.T Office Hours Call 1-917-300-0470\nFor U.S./CAN Toll Free Call 1-800-526-8630\nFor GMT Office Hours Call +353-1-416-8900\nKEYWORD:\nINDUSTRY KEYWORD: HEALTH PHARMACEUTICAL\nSOURCE: Research and Markets\nCopyright Business Wire 2022.\nPUB: 08/05/2022 06:04 AM/DISC: 08/05/2022 06:04 AM\nhttp://www.businesswire.com/news/home/20220805005176/en",
  "url": "https://apnews.com/article/science-technology-health-clinical-trials-44615f8e61574513bfada1e4b8caac84"
}